Avadel vs. Jazz Pharmaceuticals: Settled Oxybate Drug Delivery Patent War
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. |
| Case Number | 1:22-cv-00487 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Apr 2022 – Oct 2025 3 years 6 months |
| Outcome | Settled – Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Jazz Pharmaceuticals’ Xyrem® |
Case Overview
The Parties
⚖️ Plaintiff
Specialty pharmaceutical company focused on innovative drug delivery formulations, specifically the Micropump® Platform designed for once-nightly dosing.
🛡️ Defendant
Global biopharmaceutical company with a dominant position in sleep disorder therapeutics. Its sodium oxybate product Xyrem® is a flagship revenue driver.
Patents at Issue
This landmark case involved seven U.S. patents covering formulation methods, controlled-release delivery mechanisms, and dosing technologies related to oxybate compounds that shaped the modern pharmaceutical drug delivery industry:
- • US10966931B2 — Formulation methods for oxybate
- • US11147782B1 — Controlled-release delivery mechanisms
- • US8731963B1 — Dosing technologies for oxybate compounds
- • US10758488B2 — Oxybate drug formulation
- • US10959956B2 — Formulation methods for controlled release
- • US11077079B1 — Drug administration methodology
- • US10813885B1 — Dosing technologies for narcolepsy treatment
Developing a novel drug delivery system?
Check if your oxybate formulation might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case concluded via **stipulated dismissal with prejudice** under Federal Rules of Civil Procedure 41(a). All claims and counterclaims were dismissed, with each party bearing its own attorneys’ fees and costs. No damages award or injunctive relief order was entered, and the specific financial terms of any underlying Settlement Agreement were not made part of the public record.
Legal Significance
The stipulated dismissal, classified as an “Other Action” termination, does not reflect a judicial determination on the merits of infringement, validity, or enforceability. This means no precedent on patent validity or claim scope was generated for third parties. However, dismissal with prejudice legally forecloses re-litigation of these specific claims between Avadel and Jazz Pharmaceuticals, acting as a significant litigation deterrent.
Drafting patents for drug delivery?
Learn from this case. Use AI to draft stronger claims covering formulation and administration.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical drug delivery. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 7 asserted oxybate patents
- See which companies are most active in drug delivery patents
- Understand complex claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Oxybate controlled-release formulations
7 Asserted Patents
In oxybate drug delivery
Settlement Options
Often involve licensing agreements
✅ Key Takeaways
For Patent Attorneys & Litigators
Stipulated dismissal with prejudice under Rule 41(a) bars re-litigation of asserted claims without generating public precedent on validity or infringement.
Search related case law →Multi-patent assertions create leverage but demand substantial resource commitment across multi-year timelines.
Explore precedents →For R&D Teams & IP Professionals
Conduct comprehensive FTO analysis across all relevant patent families, including method-of-administration claims, before product commercialization.
Start FTO analysis for my product →Competitor patent portfolios in drug delivery can generate litigation risk even for clinically improved formulations.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.
→ Search case record 1:22-cv-00487 on PACER | Verify patent details via the USPTO Patent Full-Text Database